The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Open accessAbstract
Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death protein-1 (PD-1) antibodies], improve survival in several cancer types. Since inhibition of CTLA-4 or PD-1 leads to non-selective activation of the immune system, immune-related adverse events (irAEs) are frequent. Enterocolitis is a common irAE, currently managed with corticosteroids and, if necessary, anti-tumor necrosis factor-α therapy. Such a regimen carries a risk of serious side-effects including infections, and may potentially imply impaired antitumor effects. Vedolizumab is an anti-integrin α4β7 antibody with gut-specific immunosuppressive effects, approved for Crohn's disease and ulcerative colitis. We report a case series of seven patients with metastatic melanoma or lung cancer, treated with vedolizumab off-label for ipilimumab- or nivolumab-induced enterocolitis, from June 2014 through October 2016. Clinical, laboratory, endoscopic, and histologic data were analyzed. Patients initially received corticosteroids but were steroid-dependent and/or partially refractory. One patient was administered infliximab but was refractory. The median time from onset of enterocolitis to start of vedolizumab therapy was 79 days. Following vedolizumab therapy, all patients but one experienced steroid-free enterocolitis remission, with normalized fecal calprotectin. This was achieved after a median of 56 days from vedolizumab start, without any vedolizumab-related side-effects noted. The patient in whom vedolizumab was not successful, due to active ulcerative colitis, received vedolizumab prophylactically. This is the first case series to suggest that vedolizumab is an effective and well-tolerated therapeutic for steroid-dependent or partially refractory ICPI-induced enterocolitis. A larger prospective study to evaluate vedolizumab in this indication is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on two retrospective series, VDZ is an effective and well-tolerated therapeutic for steroid-dependent or refractory ICI-induced enterocolitis.69,70”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F., Aneja, P., Ocaña, A., Leibowitz‐Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 3,304
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P. J., Sands, B. E., Hanauer, S. B., Colombel, J., Sandborn, W. J., Assche, G. V., Axler, J. L., Kim, H. J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,892
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P. J., Hanauer, S. B., Colombel, J., Sands, B. E., Lukáš, M., Fedorak, R. N., Lee, S., Bressler, B. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,716
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I. E., Matteson, E. L., & Montori, V. M. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,470
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 235
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
Wills, B., Brahmer, J. R., & Naidoo, J. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0562-9 · Cited by 20
The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy
Medina, P. J., Jeffers, K. D., Trinh, V. A., & Harvey, R. D. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019885230 · Cited by 21
Vaziri, H., Turshudzhyan, A., & Vecchio, E. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001705 · Cited by 20
Wang, S., Peng, D., Zhu, H. S., Min, W., Xue, M., Wu, R., Shao, Y., Pan, L., & Zhu, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1053370 · Cited by 19
The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
Wetwittayakhlang, P., Tselekouni, P., Al-Jabri, R., Bessissow, T., & Lakatos, P. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062432 · Cited by 18
Harvey, C., Nahar, K. J., McKeown, J., Lo, S., Farag, S., Yousaf, N., Young, K., Tas, L., Meerveld-Eggink, A., Blank, C. U., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008232 · Cited by 18
George, A. S., Fernandez, C. J., Eapen, D., & Pappachan, J. M. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.1.21 · Cited by 18
Gorabi, A. M., Ravari, M. S., Sanaei, M., Davaran, S., Kesharwani, P., & Sahebkar, A. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109300 · Cited by 18
Checkpoint inhibitors: What gastroenterologists need to know
Ahmed∥, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i48.5433 · Cited by 17
Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition–Related Colitis
van Turenhout, S. T., Berghuis, M., Snæbjörnsson, P., Wilgenhof, S., Burgers, J. A., Haanen, J. B. A. G., & van Dieren, J. M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.026 · Cited by 17
Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report
Kunogi, Y., Tominaga, K., Abe, K., Kanazawa, M., Tanaka, T., Watanabe, S., Kondo, M., Kanamori, A., Iijima, M., Goda, K., et al. (2021) · Healthcare · doi:10.3390/healthcare9040418 · Cited by 16
Weingarden, A. R., Rubin, S. J. S., & Gubatan, J. M. B. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i8.772 · Cited by 16
Mor, A., & Strazza, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.790386 · Cited by 16
Sanz-Segura, P., Cámara, P. G., Bonilla, E. M. F., Arbonés-Mainar, J. M., & Monterde, V. B. (2020) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2020.07.009 · Cited by 15
Desmedt, V., Jauregui-Amezaga, A., Fierens, L., Aspeslagh, S., Dekervel, J., Wauters, E., Peeters, M., Sabino, J., Crapé, L., Somers, M. J. G., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.025 · Cited by 14
Immunotherapy induced enterocolitis and gastritis – What to do and when?
Cheung, V., & Brain, O. (2020) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2020.101703 · Cited by 14
Yang, W., Men, P., Xue, H., Jiang, M., & Luo, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00197 · Cited by 14
Ozawa, N., Yokobori, T., Osone, K., Katayama, C., Suga, K., Komine, C., Shibasaki, Y., Shiraishi, T., Okada, T., Kato, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92530-3 · Cited by 14
Hu, X., Wang, L., Shang, B., Wang, J., Sun, J., Liang, B., Su, L., You, W., & Jiang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094414 · Cited by 13
Miao, K., & Zhang, L. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.08.002 · Cited by 13
Grice, S., Olsson-Brown, A. C., Naisbitt, D. J., & Hammond, S. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00067 · Cited by 14
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Chen, Y. H., Kovács, T., Ferdinandy, P., & Varga, Z. V. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16405 · Cited by 12
Randhawa, M., Gaughran, G., Archer, C., Pavli, P., Morey, A. L., Ali, S. S., & Yip, D. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v10.i10.350 · Cited by 12
Toxicity of tumor immune checkpoint inhibitors—more attention should be paid
Liu, Y., Wang, H., Deng, J., Sun, C., He, Y., & Zhou, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.26 · Cited by 12
The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
Zhang, S., Liang, W., Luo, L., Sun, S., & Wang, F. (2020) · BMC Biology · doi:10.1186/s12915-020-00765-9 · Cited by 12
Checkpoint Inhibitors and the Gut
Tran, T., Tran, N. G. T., & Ho, V. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030824 · Cited by 12
Rosa, M., Jarmoliński, T., Miśkiewicz‐Migoń, I., Liszka, K., Miśkiewicz‐Bujna, J., Panasiuk, A., Frączkiewicz, J., & Ussowicz, M. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/146321 · Cited by 12
Immune-related adverse events of immune checkpoint inhibitors
Tadano, H., & Torigoe, T. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.102 · Cited by 11
Acute and Long-term Adverse Events Associated With Checkpoint Blockade
Davies, M. J. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.005 · Cited by 13
Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
Ohwada, S., Ishigami, K., Akutsu, N., & Nakase, H. (2022) · Biomedicines · doi:10.3390/biomedicines10061334 · Cited by 11
Current landscape and tailored management of immune-related adverse events
Liu, W., Luo, Z., Liu, Y., & Sun, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1078338 · Cited by 10
Challenging Cases: Management of Immune-Related Toxicity
Weber, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_209557 · Cited by 10
Hamamoto, Y., Shin, N., Hoshino, T., & Kanai∥, T. (2018) · Future Oncology · doi:10.2217/fon-2018-0509 · Cited by 10
Remission of ulcerative colitis flare-up induced by nivolumab
Iwamoto, M., Kato, K., Moriyama, M., Yamaguchi, K., & Takahashi, S. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03638-3 · Cited by 10
Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
Kaneoka, A., Okada, E., Sugino, H., Saito‐Sasaki, N., Omoto, D., & Nakamura, M. (2022) · Diagnostics · doi:10.3390/diagnostics12020480 · Cited by 10
Gapizov, S. S., Petrovskaya, L. E., Shingarova, L. N., Svirschevskaya, E. V., Dolgikh, D. A., & Kirpichnikov, M. P. (2018) · Acta Naturae · doi:10.32607/20758251-2018-10-1-34-42 · Cited by 10
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
Burke, M., & Rashdan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720759 · Cited by 9
Martínez, E. C., Robles, V., Guise, C. H.-D., Mayorga, L., Casellas, F., Herrera, M. R., & Borruel, N. (2023) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2023.9436/2022 · Cited by 9
Tran, C. N., Abu‐Sbeih, H., Luo, W., Lü, Y., & Wang, Y. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_18_18 · Cited by 9
Ma, C., MacDonald, J. K., Nguyen, T. M., Casteele, N. V., Linggi, B. E., Lefèvre, P. L. C., Wang, Y., Feagan, B. G., & Jairath, V. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-06948-w · Cited by 9
Zheng, L., Yang, X., Wei, Y., You, J., Li, H., Liao, J., & Cheng, Y. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110738 · Cited by 9
Systematic review: disease activity indices for immune checkpoint inhibitor‐associated enterocolitis
Ma, C., MacDonald, J. K., Nguyen, T. M., Chang, J., Casteele, N. V., Feagan, B. G., & Jairath, V. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16718 · Cited by 9
Shah, M., Rajha, E., Dinardo, C. D., Muckey, E., Wierda, W. G., & Yeung, S. J. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.07.015 · Cited by 8
Strouse, J., Chan, K. K., Baccile, R., He, G., Louden, D. N., Giurcanu, M. C., Singh, A., Rieth, J. M., Abdel‐Wahab, N., Katsumoto, T. R., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1499478 · Cited by 9
How should we diagnose and manage checkpoint inhibitor-associated colitis?
Khan, F., Funchain, P., Bennett, A. E., Hull, T. L., & Shen, B. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.18020 · Cited by 8
Menon, T., & Afzali, A. (2019) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-019-00263-0 · Cited by 8
Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC
Callens, R., Tamsin, A., & Zandweghe, L. V. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.014 · Cited by 8
Grover, S., & Srivastava, A. (2019) · Cancer · doi:10.1002/cncr.32005 · Cited by 8
Zenatri, M., Collins, M., Alberto, T., Farina, A., Collardeau‐Frachon, S., Saint-Jean, M., Bocquet, F., Dumont, F., Honnorat, J., Joubert, B., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03901-4 · Cited by 7
Steroid-sparing strategies for managing immune-related adverse events
Huang, J. J., Yousefiasl, M., Singh, N., Grivas, P. D., & Bhatia, S. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013776 · Cited by 7
Sanz-Segura, P., Cámara, P. G., Bonilla, E. M. F., Arbonés-Mainar, J. M., & Monterde, V. B. (2021) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2020.07.007 · Cited by 7
Kou, F., Li, J., Cao, Y., Peng, Z., Xu, T., Shen, L., Gong, J., & Wang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1285478 · Cited by 7
New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis
Velikova, T. V., Krastev, B. M., Gulinac, M., Zashev, M., Graklanov, V., & Peruhova, M. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i6.1050 · Cited by 6
D’Apolito, M., Spagnuolo, R., Siciliano, M. A., Barbieri, V., Cosco, C., Fiorillo, L., Cuomo, O., Zuccalà, V., Correale, P., Pensabene, L., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211063024 · Cited by 6
Fedyanin, M. Y., Владимирович, С. А., Breder, V. V., Linkova, Y. N., Zinkina-Orikhan, A. V., Setkina, S. B., Фогт, С. Н., Chistyakov, V., & Kravtsova, N. A. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-2-360 · Cited by 6
Abu‐Sbeih, H., Ali, F. S., Luo, W., Raju, G. S., & Wang, Y. (2019) · Gastroenterology · doi:10.1016/s0016-5085(19)37377-9 · Cited by 6
Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection
Şışman, G., Barbur, E., Saka, D., & Cetin, S. E. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02815-1 · Cited by 6
Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité
Kostine, M., Marabelle, A., Schaeverbeke, T., & Kfoury, M. (2019) · médecine/sciences · doi:10.1051/medsci/2019191 · Cited by 6
Successful management of refractory immune-mediated enterocolitis with cyclosporine
Pesántez, D., Seguí, E., Ordás, Í., Viladot, M., & Arance, A. M. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.014 · Cited by 5
Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
Zhang, Z., & Zheng, C.-Q. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i29.10550 · Cited by 5
Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review
Nakane, T., Mitsuyama, K., Yamauchi, R., Kakuma, T., & Torimura, T. (2021) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms682006 · Cited by 5
Alcantar, D. C., Al-Jashaami, L., & Giron, F. (2019) · Cureus · doi:10.7759/cureus.6392 · Cited by 5
Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis
Klemm, N. K., Trasolini, R. P., Chahal, D., & Donnellan, F. K. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.101604 · Cited by 5
Shimozaki, K., Hirata, K., Horie, S., Chida, A., Tsugaru, K., Hayashi, Y., Kawasaki, K., Miyanaga, R., Hayashi, H., Mizuno, R., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11030543 · Cited by 5
Yazaki, T., Moriyama, I., Tobita, H., Sonoyama, H., Okimoto, E., Oka, A., Mishima, Y., Oshima, N., Shibagaki, K., Kawashima, K., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7911-21 · Cited by 5
Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
Li, H., Sahu, K. K., & Maughan, B. L. (2022) · Cancers · doi:10.3390/cancers14102460 · Cited by 6
Xu, Y., Lyu, X., Qin, Y., Ma, D., Wang, M., Shi, J., Long, Y., Tang, B., & Liu, H. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14567 · Cited by 5
Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis
Kayashima, A., Shimozaki, K., Hirata, K., Mutaguchi, M., Takabayashi, K., Hayashi, Y., Hosoe, N., Ogata, H., Sujino, T., & Kanai∥, T. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01261-x · Cited by 5
Tan, Q., Mei, X.-P., Hu, Y., Wu, H., Xie, L., Xiong, J., & Yao, J. (2025) · Current Medical Science · doi:10.1007/s11596-025-00030-6 · Cited by 4
Kumar, A. B., Maus, R. L. G., & Markovic, S. N. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.03.028 · Cited by 4
Nivolumab and immune‐mediated colitis
Walker, H., Brennan, P., Groome, M., Walsh, S. V., & Carey, F. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2027 · Cited by 4
Escudero, O. G. (2024) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2023.11.001 · Cited by 4
Management of immunotherapy colitis: Special considerations in the COVID‐19 era
Grover, S., Bond, S. A., Mansour, M. K., & Friedman, S. (2020) · Cancer · doi:10.1002/cncr.33125 · Cited by 4
Zengin, Z. B., Salgia, N., Chehrazi‐Raffle, A., Meza, L., Malhotra, J., & Pal, S. K. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000473 · Cited by 4
Sullivan, R. J., Tsai, K. K., Pavlick, A. C., Buchbinder, E. I., Agarwala, S. S., Ribas, A., Jansson, J. P., Rossiter, G., & Olszanski, A. J. (2025) · Journal of Cancer · doi:10.7150/jca.117878 · Cited by 3
Esfahani, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0480-1 · Cited by 3
Update on immunotherapy‐mediated colitis: Clinical features, mechanisms, and management
Wang, D., Zhao, Y., Zeng, Y., Hu, L., & Xu, C. S. (2024) · Malignancy Spectrum · doi:10.1002/msp2.50 · Cited by 3
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Plazas, J. G., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10250/2024 · Cited by 3
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Gallego-Plazas, J., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2023.10.003 · Cited by 3
Zellweger, M., Rogler, G., Komminoth, P., Werth, L., & Breidert, M. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1652-2638 · Cited by 3
Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma
Pavlick, A. C., & Weber, J. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_60 · Cited by 3
Wan, D.-L., Chen, H., Ke, Q., Zhou, T., Ruan, L., Tang, H., & Shen, Y. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-222 · Cited by 2
Fang, J., Ruan, S., Wang, Y., Chen, Y., Huang, F., Zhang, Z., Zhang, C., Hou, B., & Huang, S. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70581 · Cited by 2
Wang, Y.-S., Zheng, A.-H., Zhao, J., Gu, H.-Y., Meng, Z.-N., Chen, J.-Y., Wang, F.-W., Zhu, X.-M., Chen, Y., Xu, S.-C., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112417 · Cited by 2
Endoscopic scoring of immune-mediated colitis disease activity
Bergqvist, V., Gedeon, P., Hertervig, E., & Marsal, J. (2025) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.10.007 · Cited by 2
Self-citationYelehe‐Okouma, M., Granel‐Brocard, F., Hudziak, H., Schmutz, J. ‐., & Gillet, P. (2017) · Therapies · doi:10.1016/j.therap.2017.10.004 · Cited by 2
Juřica, J., & Turjap, M. (2025) · Česká a slovenská farmacie · doi:10.36290/csf.2025.003 · Cited by 1
Immune Checkpoint-Induced Colitis: A Single-Center Retrospective Cohort Study
Holder, B., Vereecke, J., Ureel, N., Lobatón, T., Hoorens, A., Lievens, A., Truyens, M., Rottey, S., Vermaelen, K. Y., D'Cruz, V., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207219 · Cited by 1
Lu, T., Song, X., Zhang, T., & Ge, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1810121 · Cited by 1
Calabrich, A., Wainstein, A. J. A., de Melo, A. C., Buzaid, A. C., Katz, A., Ferreira, C. G., dos Anjos, C. H., Baldotto, C. S. D. R., Mathias, C. M. D. C., Gomes, E. E., et al. (2022) · Brazilian Journal of Oncology · doi:10.5935/2526-8732.20220305 · Cited by 1
Tauseef, A., Zafar, M., Siddiqui, S. A. H., Dufani, J., DeVrieze, B., Mirza, M., Thirumalareddy, J., Sood, A., & Mirza, M. M. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1438_23 · Cited by 1
Petrousis, G., Szczegielniak, S., Sabhan, H., Elbe, P., Bilican, G., Strid, H., Bresso, F., Hedin, C. R. H., & Haas, S. (2025) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v17.i7.107798 · Cited by 1
George, A. S., Fernandez, C. J., Eapen, D., & Pappachan, J. M. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.1.1.21 · Cited by 1
Abid, H., & Ali, S. A. N. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.08.074 · Cited by 1
Hammami, M. B., Gill, R. M., Thiruvengadam, N. R., Oh, D. Y., Beck, K. R., Mahadevan, U., & Kattah, M. G. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05534-5 · Cited by 1
Gastrointestinal side effects of immune checkpoint inhibitors: new topic for gastroncologists
Paydaş, S. (2019) · Hematology & Medical Oncology · doi:10.15761/hmo.1000181 · Cited by 1
Nivolumab Induced Autoimmune Like Gastritis: A Case Report
Mubde, A. M. (2020) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2020.09.001358 · Cited by 1
Chronic diarrhoea in an oncology patient – Clinical assessment and decision making
Fernandes, D., & Andreyev, J. N. (2020) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2020.101708 · Cited by 1
Toxicities of Novel Antineoplastic Therapies
Rajha, E., & Yeung, S. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-67123-5_53 · Cited by 1
Cardeña-Gutiérrez, A., Mielgo-Rubio, X., Muñoz, M. R., Cabañes, R. M., Muñoz, D. M., Polo, S. H., Olier, C., Nuño, A. H., Peña, V. S., Becerra, M. V. S., et al. (2021) · F1000Research · doi:10.12688/f1000research.53327.1 · Cited by 1
Metadata
- Authors
- Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J.
- Affiliations
- Skåne University Hospital (SE)
- Lund University (SE)
- Corresponding author
- Marsal, Jan
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2017-02-15
- Volume
- 66
- Issue
- 5
- Pages
- 581-592
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC5406433
- OpenAlex
- W2588366403
- Cited by
- 234
- References
- 56
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 20 · 2023: 13 · 2022: 24 · 2021: 33 · 2020: 41 · 2019: 37 · 2018: 35 · 2017: 6
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Hedlund Foundation
- Alfred Österlunds Stiftelse
- Julin Foundation
- Kungliga Fysiografiska Sällskapet i Lund
- Svenska Läkaresällskapet
- Grants to researchers in the public health care from the Swedish government (ALFSKANE-539811)
- Healthcare Region of Southern Sweden
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- vedolizumab, immune-related adverse events, ipilimumab, nivolumab, pembrolizumab, CTLA-4, PD-1, metastatic melanoma, lung cancer, off-label drug use, fecal calprotectin, ulcerative colitis
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Enterocolitis, Female, Gastrointestinal Agents, Humans, Lung Neoplasms, Male, Melanoma, Middle Aged, Cell Cycle Checkpoints, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
